AlphAIalphai — Financial news for AI agents
yahoo.comAUG 117 min read$IDXX

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.

Original reporting
yahoo.com
Published Aug 11, 2026, 5:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
IDEXX (IDXX) Q2 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$IDXXBullishHigh
01

Why it matters

Traders can update 2026 revenue and EPS models immediately using the raised ranges, while monitoring recurring revenue growth drivers (CAG Diagnostics, VetLab consumables, reference lab) versus wellness-visit softness and FX effects.

02

Market read

Raised 2026 revenue and EPS guidance, supported by recurring revenue growth and margin expansion, is the primary tradable catalyst.

03

What to watch

FX headwinds and the instrument revenue decline from lapping inVue Dx availability could create volatility in quarterly revenue mix even if full-year guidance holds.

Relevance 9/10Novelty 9/10Timing: post-close guidance update for 2026 outlook

Background

The article is an IDEXX Q2 2026 earnings call transcript covering segment performance, margins, cash flow, and an updated full-year outlook.

Company-level read

Ticker impact

$IDXXBullishHigh confidence
Context

IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94 after Q2 EPS of $4.27.

Expected impact

Likely positive near-term bias as traders reprice 2026 estimates toward the raised revenue and EPS ranges.

Evidence & confidence

The transcript includes explicit updated full-year revenue and EPS ranges, supported by reported Q2 EPS growth and margin expansion, which are direct inputs to valuation and estimate revisions.

Market effects

Sector

Signals continued strength in veterinary diagnostics recurring revenue and instrument placements, potentially supportive for sentiment across animal health diagnostics peers.

Regional

International CAG Diagnostics recurring revenue grew nearly 12% organically, suggesting non-US demand resilience.

Global

Water and LPD growth plus reference lab volume gains indicate broad-based performance, reducing reliance on any single geography or modality.

Counterpoint

What could challenge this read

Wellness visit pressure is still described as the primary constraint to clinical visits, which could cap upside if it worsens despite instrument and consumables momentum.

Key entities

  • company
    IDEXX

    Veterinary diagnostics and software company providing Q2 results and raising 2026 revenue and EPS outlook.

Read at source← All news

Related articles

AUG 6
$IDXXMedAI 8/10

IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary

IDEXX Laboratories reported Q2 2026 results driven by 10.3% organic growth in CAG Diagnostics recurring revenue, while U.S. same-store clinical visits fell 1.3%. Management raised full-year organic revenue growth guidance to 8.5% to 9.7% despite a $15 million FX headwind and expects U.S. visits to decline 1.5% in H2. Operating margin rose 110 bps.

yahoo.com7 min
AUG 6
$IDXXHighAI 9/10

IDEXX Laboratories Q2 Earnings Call Highlights

IDEXX (NASDAQ:IDXX) highlighted Q2 results and product updates on its earnings call. VetLab consumables rose 14% organically, Global Reference Laboratory revenue grew over 10% organically, and Rapid Assay revenue returned to growth. IDEXX placed 5,265 premium instruments, including 1,602 inVue Dx analyzers, and raised 2026 revenue outlook to $4.70-$4.745B and EPS to $14.69-$14.94.

yahoo.com6 min
AUG 4
$IDXXMedAI 8/10

Why is IDEXX Laboratories stock rallying today?

Investing.com reports IDEXX Laboratories shares rose 3.9% in pre-open after Q2 2026 results beat expectations. Adjusted EPS was $4.27 vs $3.96 consensus, and revenue was $1.22B vs $1.20B. The company raised and narrowed FY2026 guidance to EPS $14.69-$14.94 and revenue $4.70-$4.75B. U.S. equity futures were also higher.

investing.com3 min
AUG 4
$IDXXHigh

IDEXX LABORATORIES INC /DE (IDXX): Results of Operations and Financial Condition

IDEXX LABORATORIES INC /DE (IDXX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622041d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ▪ Strong vol

SEC EDGAR 8-K6 min
AUG 26
$NVDAHighAI 8/10

Nvidia Is Hours Away From Testing Every Investor

Nvidia (NVDA) is set to report fiscal Q2 2027 earnings on August 26, 2026. Analysts expect $92.07B revenue and $2.09 EPS, with guidance being the key focus. Nvidia's stock is heavily weighted in major index funds, making its performance impactful for many investors. Analysts' revenue estimates range from $94B to $95B for Q2 and $107B to $108B for Q3. China revenue and AI financing are also key topics.

aol.com3 min